CHUC — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-17

• PACHA flavored 4mL, 8mL, and 12mL Disposables, as well as the Company’s PACHA e-liquids, have all been submitted for approval for inclusion on the Alabama State Directory.

• PACHAMAMA 2020 e-liquids, have all been submitted for approval to Iowa, Pennsylvania and South Carolina.

• With a growing number of states instituting state registries each year, we believe that Pachamama, and PACHA and (non-nicotine) SBX will expect to see continued (and growing) success in the marketplace and that Charlie’s competitive advantages will expand significantly.

• On May 19, 2026, the Company completed a private placement of 6,350,000 shares of its common stock at a purchase price of $0.20 per share, resulting in aggregate consideration of $1,670,000. Of the total consideration, $270,000 was received in cash, $868,000 of which was paid in the form of debt and…

• On June 23, 2026, the FDA notified us that certain of our PACHA products (30 SKUs) for which PMTAs have been submitted have been tentatively identified for inclusion on the FDA's public-facing webpage of products for which the FDA generally does not intend to prioritize enforcement of premarket auth…

Text removed vs the prior filing · source: 10-Q · 2026-05-20

• With growing number of states instituting state registries each year, we believe that Pachamama, and PACHA and (non-nicotine) SBX will expect to see continued (and growing) success in the marketplace and that Charlie’s competitive advantages will expand significantly.

• On May 20, 2026, the Company completed a private placement of 8,750,000 shares of its common stock at a purchase price of $0.20 per share, resulting in aggregate consideration of $1,750,000. Of the total consideration, $750,000 was received in cash and $1,000,000 was satisfied through the forgivenes…

• Results of Operations for the Three Months Ended March 31, 2026 Compared to the Three Months Ended March 31, 2025

• A review of the three-month period ended March 31, 2026, follows:

• Revenue for the three months ended March 31, 2026, increased by approximately $3,226,000 or 204.4%, to approximately $4,804,000, as compared to approximately $1,578,000 for same period in 2025, which is all due to the increase in our nicotine-based product and nicotine alternative products sales. Sa…

Text added vs the prior filing · source: 10-Q · 2026-08-17

• As of the date, there are no proceedings in which any of our directors, executive officers or affiliates, or any registered or beneficial stockholder, is an adverse party or has a material interest adverse to our interest.

• As more fully described under “Risks and Uncertainties” (above), and in our 2025 Annual Report in “RISK FACTORS,” the Company’s wholly owned subsidiary, Charlie’s Chalk Dust LLC (“CCD”), is a petitioner in two proceedings challenging Marketing Denial Orders (“MDOs”) issued by the U.S. Food and Drug …

• On April 1, 2026, the FDA issued an MDO to CCD covering certain products included in CCD’s timely submitted 2020 PMTA. On May 1, 2026, CCD and Toro Imports LLC filed a petition for review challenging the MDO in the U.S. Court of Appeals for the Fifth Circuit, Charlie’s Chalk Dust LLC, et al. v. U.S.…

• On October 28, 2025, the FDA issued MDOs to CCD covering certain products included in CCD’s timely submitted 2022 PMTAs. CCD and FOK of Houma LLC, doing business as Nocko’s, filed a petition for review challenging the MDOs in the U.S. Court of Appeals for the Fifth Circuit, Charlie’s Chalk Dust LLC,…

• Except for these proceedings, the Company is not a party to any material legal or administrative proceeding.

Text removed vs the prior filing · source: 10-Q · 2026-05-20

• As of the date hereof, we are not a party to any material legal or administrative proceedings. There are no proceedings in which any of our directors, executive officers or affiliates, or any registered or beneficial stockholder, is an adverse party or has a material interest adverse to our interest…